{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T11:45:09Z","timestamp":1792755909423,"version":"4.5.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,18]],"date-time":"2024-11-18T00:00:00Z","timestamp":1731888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,18]],"date-time":"2024-11-18T00:00:00Z","timestamp":1731888000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100006492","name":"Division of Intramural Research, National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01AI127863"],"award-info":[{"award-number":["R01AI127863"]}],"id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006492","name":"Division of Intramural Research, National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R21AI164733"],"award-info":[{"award-number":["R21AI164733"]}],"id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006492","name":"Division of Intramural Research, National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R21AI164733"],"award-info":[{"award-number":["R21AI164733"]}],"id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"DOI":"10.1038\/s41541-024-01018-4","type":"journal-article","created":{"date-parts":[[2024,11,18]],"date-time":"2024-11-18T01:34:08Z","timestamp":1731893648000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["NHBA antibodies elicited by 4CMenB vaccination are key for serum bactericidal activity against Neisseria gonorrhoeae"],"prefix":"10.1038","volume":"9","author":[{"given":"Yih-Ling","family":"Tzeng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soma","family":"Sannigrahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Stephens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,18]]},"reference":[{"key":"1018_CR1","unstructured":"WHO. Multi-Drug Resistant Gonorrhoea, <https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/multi-drug-resistant-gonorrhoea> (2023)."},{"key":"1018_CR2","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1097\/OLQ.0000000000001355","volume":"48","author":"KM Kreisel","year":"2021","unstructured":"Kreisel, K. M. et al. Sexually transmitted infections among US women and men: prevalence and incidence estimates, 2018. Sex. Transm. Dis. 48, 208\u2013214 (2021).","journal-title":"Sex. Transm. Dis."},{"key":"1018_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr7004a1","volume":"70","author":"KA Workowski","year":"2021","unstructured":"Workowski, K. A. et al. Sexually transmitted infections treatment guidelines, 2021. MMWR Recomm. Rep. 70, 1\u2013187 (2021).","journal-title":"MMWR Recomm. Rep."},{"key":"1018_CR4","doi-asserted-by":"publisher","first-page":"e532","DOI":"10.1016\/S1473-3099(24)00001-X","volume":"24","author":"LT Allan-Blitz","year":"2024","unstructured":"Allan-Blitz, L. T., Fifer, H. & Klausner, J. D. Managing treatment failure in Neisseria gonorrhoeae infection: current guidelines and future directions. Lancet Infect. Dis. 24, e532\u2013e538 (2024).","journal-title":"Lancet Infect. Dis."},{"key":"1018_CR5","doi-asserted-by":"publisher","first-page":"S95","DOI":"10.1093\/cid\/ciac043","volume":"74","author":"LA Barbee","year":"2022","unstructured":"Barbee, L. A. & St Cyr, S. B. Management of Neisseria gonorrhoeae in the United States: Summary of evidence from the development of the 2020 Gonorrhea treatment recommendations and the 2021 Centers for disease control and prevention sexually transmitted infection treatment guidelines. Clin. Infect. Dis. 74, S95\u2013S111 (2022).","journal-title":"Clin. Infect. Dis."},{"key":"1018_CR6","doi-asserted-by":"publisher","first-page":"S89","DOI":"10.1093\/cid\/ciab1055","volume":"74","author":"KA Workowski","year":"2022","unstructured":"Workowski, K. A. & Bachmann, L. H. Centers for disease control and prevention\u2019s sexually transmitted diseases infection guidelines. Clin. Infect. Dis. 74, S89\u2013S94 (2022).","journal-title":"Clin. Infect. Dis."},{"key":"1018_CR7","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.3201\/eid2206.151093","volume":"22","author":"J Whelan","year":"2016","unstructured":"Whelan, J., Klovstad, H., Haugen, I. L., Holle, M. R. & Storsaeter, J. Ecologic study of meningococcal B vaccine and Neisseria gonorrhoeae Infection, Norway. Emerg. Infect. Dis. 22, 1137\u20131139 (2016).","journal-title":"Emerg. Infect. Dis."},{"key":"1018_CR8","first-page":"53","volume":"18","author":"O P\u00e9rez","year":"2009","unstructured":"P\u00e9rez, O. et al. Mucosal approaches in Neisseria vaccinology. VacciMonitor 18, 53\u201355 (2009).","journal-title":"VacciMonitor"},{"key":"1018_CR9","doi-asserted-by":"publisher","first-page":"683","DOI":"10.3389\/fimmu.2019.00683","volume":"10","author":"H Petousis-Harris","year":"2019","unstructured":"Petousis-Harris, H. & Radcliff, F. J. Exploitation of Neisseria meningitidis Group B OMV vaccines against N. gonorrhoeae to inform the development and deployment of effective gonorrhea vaccines. Front Immunol. 10, 683 (2019).","journal-title":"Front Immunol."},{"key":"1018_CR10","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1016\/S0140-6736(17)31449-6","volume":"390","author":"H Petousis-Harris","year":"2017","unstructured":"Petousis-Harris, H. et al. Effectiveness of a group B outer membrane vesicle meningococcal vaccine against gonorrhoea in New Zealand: a retrospective case-control study. Lancet 390, 1603\u20131610 (2017).","journal-title":"Lancet"},{"key":"1018_CR11","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/S1473-3099(21)00812-4","volume":"22","author":"WE Abara","year":"2022","unstructured":"Abara, W. E. et al. Effectiveness of a serogroup B outer membrane vesicle meningococcal vaccine against gonorrhoea: a retrospective observational study. Lancet Infect. Dis. 22, 1021\u20131029 (2022).","journal-title":"Lancet Infect. Dis."},{"key":"1018_CR12","doi-asserted-by":"publisher","first-page":"e1341","DOI":"10.1093\/cid\/ciac436","volume":"76","author":"KJ Bruxvoort","year":"2023","unstructured":"Bruxvoort, K. J. et al. Prevention of Neisseria gonorrhoeae with meningococcal B vaccine: a matched cohort study in Southern California. Clin. Infect. Dis. 76, e1341\u2013e1349 (2023).","journal-title":"Clin. Infect. Dis."},{"key":"1018_CR13","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/S1473-3099(21)00754-4","volume":"22","author":"B Wang","year":"2022","unstructured":"Wang, B. et al. Effectiveness and impact of the 4CMenB vaccine against invasive serogroup B meningococcal disease and gonorrhoea in an infant, child, and adolescent programme: an observational cohort and case-control study. Lancet Infect. Dis. 22, 1011\u20131020 (2022).","journal-title":"Lancet Infect. Dis."},{"key":"1018_CR14","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1080\/14760584.2018.1547637","volume":"17","author":"R Rappuoli","year":"2018","unstructured":"Rappuoli, R., Pizza, M., Masignani, V. & Vadivelu, K. Meningococcal B vaccine (4CMenB): the journey from research to real world experience. Expert Rev. Vaccines 17, 1111\u20131121 (2018).","journal-title":"Expert Rev. Vaccines"},{"key":"1018_CR15","doi-asserted-by":"publisher","first-page":"3770","DOI":"10.1073\/pnas.0915162107","volume":"107","author":"D Serruto","year":"2010","unstructured":"Serruto, D. et al. Neisseria meningitidis GNA2132, a heparin-binding protein that induces protective immunity in humans. Proc. Natl. Acad. Sci. USA 107, 3770\u20133775 (2010).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1018_CR16","doi-asserted-by":"publisher","unstructured":"Marjuki, H. et al. Genetic similarity of gonococcal homologs to meningococcal outer membrane proteins of serogroup B vaccine. mBio 10, https:\/\/doi.org\/10.1128\/mBio.01668-19 (2019).","DOI":"10.1128\/mBio.01668-19"},{"key":"1018_CR17","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1096\/fj.14-263954","volume":"29","author":"D Donnarumma","year":"2015","unstructured":"Donnarumma, D. et al. Neisseria meningitis GNA1030 is a ubiquinone-8 binding protein. FASEB 29, 2260\u20132267 (2015).","journal-title":"FASEB"},{"key":"1018_CR18","doi-asserted-by":"publisher","first-page":"15602","DOI":"10.1074\/jbc.M113.539510","volume":"289","author":"MP Bos","year":"2014","unstructured":"Bos, M. P., Grijpstra, J., Tommassen-van Boxtel, R. & Tommassen, J. Involvement of Neisseria meningitidis lipoprotein GNA2091 in the assembly of a subset of outer membrane proteins. J. Biol. Chem. 289, 15602\u201315610 (2014).","journal-title":"J. Biol. Chem."},{"key":"1018_CR19","doi-asserted-by":"publisher","first-page":"e1003528","DOI":"10.1371\/journal.ppat.1003528","volume":"9","author":"I Jongerius","year":"2013","unstructured":"Jongerius, I. et al. Distinct binding and immunogenic properties of the gonococcal homologue of meningococcal factor H binding protein. PLoS Pathog. 9, e1003528 (2013).","journal-title":"PLoS Pathog."},{"key":"1018_CR20","doi-asserted-by":"publisher","first-page":"1350344","DOI":"10.3389\/fimmu.2024.1350344","volume":"15","author":"YL Tzeng","year":"2024","unstructured":"Tzeng, Y. L., Sannigrahi, S., Borrow, R. & Stephens, D. S. Neisseria gonorrhoeae lipooligosaccharide glycan epitopes recognized by bactericidal IgG antibodies elicited by the meningococcal group B-directed vaccine, MenB-4C. Front Immunol. 15, 1350344 (2024).","journal-title":"Front Immunol."},{"key":"1018_CR21","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1093\/cid\/ciy1061","volume":"69","author":"EA Semchenko","year":"2019","unstructured":"Semchenko, E. A., Tan, A., Borrow, R. & Seib, K. L. The serogroup B meningococcal vaccine Bexsero elicits antibodies to Neisseria gonorrhoeae. Clin. Infect. Dis. 69, 1101\u20131111 (2019).","journal-title":"Clin. Infect. Dis."},{"key":"1018_CR22","doi-asserted-by":"publisher","first-page":"e1008602","DOI":"10.1371\/journal.ppat.1008602","volume":"16","author":"I Leduc","year":"2020","unstructured":"Leduc, I. et al. The serogroup B meningococcal outer membrane vesicle-based vaccine 4CMenB induces cross-species protection against Neisseria gonorrhoeae. PLoS Pathog. 16, e1008602 (2020).","journal-title":"PLoS Pathog."},{"key":"1018_CR23","doi-asserted-by":"publisher","first-page":"3322","DOI":"10.1016\/j.vaccine.2015.05.027","volume":"33","author":"J Findlow","year":"2015","unstructured":"Findlow, J. et al. Safety and immunogenicity of a four-component meningococcal group B vaccine (4CMenB) and a quadrivalent meningococcal group ACWY conjugate vaccine administered concomitantly in healthy laboratory workers. Vaccine 33, 3322\u20133330 (2015).","journal-title":"Vaccine"},{"key":"1018_CR24","doi-asserted-by":"publisher","first-page":"4237","DOI":"10.1073\/pnas.1620971114","volume":"114","author":"YL Tzeng","year":"2017","unstructured":"Tzeng, Y. L. et al. Emergence of a new Neisseria meningitidis clonal complex 11 lineage 11.2 clade as an effective urogenital pathogen. Proc. Natl. Acad. Sci. USA 114, 4237\u20134242 (2017).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1018_CR25","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1128\/CVI.00036-08","volume":"15","author":"JS Plested","year":"2008","unstructured":"Plested, J. S. & Granoff, D. M. Vaccine-induced opsonophagocytic immunity to Neisseria meningitidis group B. Clin. Vaccin. Immunol. 15, 799\u2013804 (2008).","journal-title":"Clin. Vaccin. Immunol."},{"key":"1018_CR26","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1084\/jem.129.6.1307","volume":"129","author":"I Goldschneider","year":"1969","unstructured":"Goldschneider, I., Gotschlich, E. C. & Artenstein, M. S. Human immunity to the meningococcus. I. The role of humoral antibodies. J. Exp. Med 129, 1307\u20131326 (1969).","journal-title":"J. Exp. Med"},{"key":"1018_CR27","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1080\/14760584.2022.2050697","volume":"21","author":"V Viviani","year":"2022","unstructured":"Viviani, V., Biolchi, A. & Pizza, M. Synergistic activity of antibodies in the multicomponent 4CMenB vaccine. Expert Rev. Vaccines 21, 645\u2013658 (2022).","journal-title":"Expert Rev. Vaccines"},{"key":"1018_CR28","doi-asserted-by":"publisher","first-page":"e0162878","DOI":"10.1371\/journal.pone.0162878","volume":"11","author":"I Vacca","year":"2016","unstructured":"Vacca, I. et al. Neisserial heparin binding antigen (NHBA) contributes to the adhesion of Neisseria meningitidis to human epithelial cells. PLoS ONE 11, e0162878 (2016).","journal-title":"PLoS ONE"},{"key":"1018_CR29","doi-asserted-by":"publisher","first-page":"41767","DOI":"10.1074\/jbc.M111.289314","volume":"286","author":"V Esposito","year":"2011","unstructured":"Esposito, V. et al. Structure of the C-terminal domain of Neisseria heparin binding antigen (NHBA), one of the main antigens of a novel vaccine against Neisseria meningitidis. J. Biol. Chem. 286, 41767\u201341775 (2011).","journal-title":"J. Biol. Chem."},{"key":"1018_CR30","doi-asserted-by":"publisher","first-page":"e0201922","DOI":"10.1371\/journal.pone.0201922","volume":"13","author":"M Maritan","year":"2018","unstructured":"Maritan, M. et al. Structures of NHBA elucidate a broadly conserved epitope identified by a vaccine induced antibody. PLoS ONE 13, e0201922 (2018).","journal-title":"PLoS ONE"},{"key":"1018_CR31","doi-asserted-by":"publisher","first-page":"4236","DOI":"10.1016\/j.vaccine.2017.06.020","volume":"35","author":"E Partridge","year":"2017","unstructured":"Partridge, E., Lujan, E., Giuntini, S., Vu, D. M. & Granoff, D. M. The role of anti-NHba antibody in bactericidal activity elicited by the meningococcal serogroup B vaccine, MenB-4C. Vaccine 35, 4236\u20134244 (2017).","journal-title":"Vaccine"},{"key":"1018_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-023-00651-9","volume":"8","author":"V Viviani","year":"2023","unstructured":"Viviani, V. et al. OpcA and PorB are novel bactericidal antigens of the 4CMenB vaccine in mice and humans. NPJ Vaccines 8, 54 (2023).","journal-title":"NPJ Vaccines"},{"key":"1018_CR33","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1016\/j.vaccine.2014.01.011","volume":"32","author":"C Tani","year":"2014","unstructured":"Tani, C. et al. Quantification by LC-MS(E) of outer membrane vesicle proteins of the Bexsero(R) vaccine. Vaccine 32, 1273\u20131279 (2014).","journal-title":"Vaccine"},{"key":"1018_CR34","doi-asserted-by":"publisher","unstructured":"Borghi, S. et al. Multilayer regulation of Neisseria meningitidis NHBA at physiologically relevant temperatures. Microorganisms 10, https:\/\/doi.org\/10.3390\/microorganisms10040834 (2022).","DOI":"10.3390\/microorganisms10040834"},{"key":"1018_CR35","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1097\/00005537-200004000-00021","volume":"110","author":"T Keck","year":"2000","unstructured":"Keck, T., Leiacker, R., Riechelmann, H. & Rettinger, G. Temperature profile in the nasal cavity. Laryngoscope 110, 651\u2013654 (2000).","journal-title":"Laryngoscope"},{"key":"1018_CR36","doi-asserted-by":"publisher","first-page":"43","DOI":"10.4037\/ajcc2018865","volume":"27","author":"HM Schell-Chaple","year":"2018","unstructured":"Schell-Chaple, H. M., Liu, K. D., Matthay, M. A. & Puntillo, K. A. Rectal and bladder temperatures vs forehead core temperatures measured with SpotOn monitoring system. Am. J. Crit. Care 27, 43\u201350 (2018).","journal-title":"Am. J. Crit. Care"},{"key":"1018_CR37","doi-asserted-by":"publisher","unstructured":"Semchenko, E. A., Day, C. J. & Seib, K. L. The Neisseria gonorrhoeae vaccine candidate NHBA elicits antibodies that are bactericidal, opsonophagocytic and that reduce gonococcal adherence to epithelial cells. Vaccines 8, https:\/\/doi.org\/10.3390\/vaccines8020219 (2020).","DOI":"10.3390\/vaccines8020219"},{"key":"1018_CR38","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1093\/infdis\/jiz628","volume":"221","author":"EA Semchenko","year":"2020","unstructured":"Semchenko, E. A., Mubaiwa, T. D., Day, C. J. & Seib, K. L. Role of the gonococcal Neisserial heparin binding antigen in microcolony formation, and serum resistance and adherence to epithelial cells. J. Infect. Dis. 221, 1612\u20131622 (2020).","journal-title":"J. Infect. Dis."},{"key":"1018_CR39","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1086\/379375","volume":"188","author":"JA Welsch","year":"2003","unstructured":"Welsch, J. A. et al. Antibody to genome-derived neisserial antigen 2132, a Neisseria meningitidis candidate vaccine, confers protection against bacteremia in the absence of complement-mediated bactericidal activity. J. Infect. Dis. 188, 1730\u20131740 (2003).","journal-title":"J. Infect. Dis."},{"key":"1018_CR40","doi-asserted-by":"publisher","first-page":"3751","DOI":"10.1128\/IAI.05182-11","volume":"79","author":"S Giuntini","year":"2011","unstructured":"Giuntini, S., Reason, D. C. & Granoff, D. M. Complement-mediated bactericidal activity of anti-factor H binding protein monoclonal antibodies against the meningococcus relies upon blocking factor H binding. Infect. Immun. 79, 3751\u20133759 (2011).","journal-title":"Infect. Immun."},{"key":"1018_CR41","doi-asserted-by":"publisher","first-page":"10329","DOI":"10.1096\/fj.201902795R","volume":"34","author":"EN Natali","year":"2020","unstructured":"Natali, E. N. et al. Synergic complement-mediated bactericidal activity of monoclonal antibodies with distinct specificity. FASEB 34, 10329\u201310341 (2020).","journal-title":"FASEB"},{"key":"1018_CR42","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/BF00415518","volume":"53","author":"PA Rice","year":"1987","unstructured":"Rice, P. A., Blake, M. S. & Joiner, K. A. Mechanisms of stable serum resistance of Neisseria gonorrhoeae. Antonie Van Leeuwenhoek 53, 565\u2013574 (1987).","journal-title":"Antonie Van Leeuwenhoek"},{"key":"1018_CR43","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/j.1749-6632.1994.tb44234.x","volume":"730","author":"PA Rice","year":"1994","unstructured":"Rice, P. A. et al. Serum resistance of Neisseria gonorrhoeae. Does it thwart the inflammatory response and facilitate the transmission of infection? Ann. N. Y Acad. Sci. 730, 7\u201314 (1994).","journal-title":"Ann. N. Y Acad. Sci."},{"key":"1018_CR44","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1093\/infdis\/130.6.619","volume":"130","author":"MA Apicella","year":"1974","unstructured":"Apicella, M. A. Antigenically distinct populations of Neisseria gonorrhoeae: isolation and characterization of the responsible determinants. J. Infect. Dis. 130, 619\u2013625 (1974).","journal-title":"J. Infect. Dis."},{"key":"1018_CR45","doi-asserted-by":"crossref","unstructured":"Tzeng, Y. L. et al. Heteroresistance to the model antimicrobial peptide polymyxin B in the emerging Neisseria meningitidis lineage 11.2 urethritis clade: mutations in the pilMNOPQ operon. Mol. Microbiol. 111, 254\u2013268 (2019).","DOI":"10.1111\/mmi.14153"},{"key":"1018_CR46","doi-asserted-by":"publisher","unstructured":"Beernink, P. T., Vianzon, V., Lewis, L. A., Moe, G. R. & Granoff, D. M. A meningococcal outer membrane vesicle vaccine with overexpressed mutant FHbp elicits higher protective antibody responses in infant Rhesus macaques than a licensed serogroup B vaccine. mBio 10, https:\/\/doi.org\/10.1128\/mBio.01231-19 (2019).","DOI":"10.1128\/mBio.01231-19"},{"key":"1018_CR47","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1177\/0004563221992088","volume":"58","author":"RM West","year":"2021","unstructured":"West, R. M. Best practice in statistics: use the Welch t-test when testing the difference between two groups. Ann. Clin. Biochem. 58, 267\u2013269 (2021).","journal-title":"Ann. Clin. Biochem."}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-024-01018-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-024-01018-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-024-01018-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,18]],"date-time":"2024-11-18T14:04:10Z","timestamp":1731938650000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-024-01018-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,18]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1018"],"URL":"https:\/\/doi.org\/10.1038\/s41541-024-01018-4","relation":{},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,18]]},"assertion":[{"value":"3 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors declare no financial or non-financial competing interests and the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. This work has been presented in part at the 23rd International Pathogenic <i>Neisseria<\/i> Conference (September 2023; Boston, MA, USA).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"223"}}